FDMT Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 105065 min ago

@ $27.97

Ausgestellt: 14 Feb 2024 @ 21:13

Rendite: -16.88%

Vorheriges Signal: Feb 14 - 19:43

Vorheriges Signal: Kaufen

Rendite: 2.04 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):

Stats
Tagesvolumen	317 415
Durchschnittsvolumen	1.21M
Marktkapitalisierung	1.19B
EPS	$0 ( 2024-03-20 )
Nächstes Ertragsdatum	( $-0.730 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.01
ATR14	$0.0280 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Bizily Scott	Sell	1 250	Stock Option (Right To Buy)
2024-04-16	Bizily Scott	Sell	500	Stock Option (Right To Buy)
2024-04-16	Bizily Scott	Buy	1 250	Common Stock
2024-04-16	Bizily Scott	Buy	500	Common Stock
2024-04-16	Bizily Scott	Sell	1 750	Common Stock

INSIDER POWER
31.08
Last 99 transactions
Buy: 3 571 023 \| Sell: 1 811 773

Volumen Korrelation

Lang: -0.14 (neutral)

Kurz: 0.80 (moderate)

Signal:(50.646) Neutral

4D Molecular Korrelation

10 Am meisten positiv korreliert
AFYA	0.848
RMCF	0.839
GOEV	0.826
NTCT	0.826
SLM	0.821
IMGN	0.818
TRMK	0.817
NDAQ	0.817
PRCT	0.816
LSXMA	0.816

10 Am meisten negativ korreliert
ISDX	-0.838
ZIONP	-0.827
TRHC	-0.826
NVSAU	-0.823
KSICU	-0.822
IOAC	-0.821
GRBK	-0.815
XFIN	-0.813
VRIG	-0.812
BRIVU	-0.81

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

4D Molecular Korrelation - Währung/Rohstoff

0.38
( neutral )

0.31
( neutral )

0.00
( neutral )

0.38
( neutral )

-0.29
( neutral )

-0.32
( neutral )

4D Molecular Finanzdaten

Annual	2023
Umsatz:	$20.72M
Bruttogewinn:	$14.97M (72.26 %)
EPS:	$-2.58

FY	2023
Umsatz:	$20.72M
Bruttogewinn:	$14.97M (72.26 %)
EPS:	$-2.58

FY	2022
Umsatz:	$3.13M
Bruttogewinn:	$-751 000 (-24.00 %)
EPS:	$-3.12

FY	2021
Umsatz:	$18.04M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-11.09

Financial Reports:

No articles found.

4D Molecular

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.